Cost-Effectiveness Of Idelalisib In Combination With Rituximab For The Treatment Of Relapsed/Refractory Chronic Lymphocytic Leukemia (Cll) In Portugal
Abstract
Authors
M Gouveia MG Silva J Alarcão F Fiorentino J Carda R Costa JM Mariz J Raposo J Costa M Borges